Skip to main content
TG THERAPEUTICS, INC. logo

TG THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · TGTX ISIN · US88322Q1085 LEI · 529900X21UKABN9NJ529 US Manufacturing
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2021-06-23 Director's Dealing
Country US United States of America
Listing US TGTX

About TG THERAPEUTICS, INC.

https://www.tgtherapeutics.com/

TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company's primary area of focus is autoimmune diseases, particularly multiple sclerosis (MS). Its lead commercial product is BRIUMVI® (ublituximab), an approved therapy for adults with relapsing forms of MS. TG Therapeutics also develops a pipeline of potential therapies for B-cell malignancies and other autoimmune conditions, including investigational CAR-T cell therapies.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2021-06-23 English
OWNERSHIP DOCUMENT
Director's Dealing
2021-06-23 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on changes in the company's board and senior management, specifically the appointment of a lead independent director, changes in the chairman's title, and details about the employment agreement of the CEO. There are no financial statements or earnings data, nor is this a report of voting results or a proxy statement. The primary subject is management changes and related agreements. Therefore, the document fits the category of Board/Management Information (MANG). The document length is sufficient and contains detailed information about management changes, not just an announcement or summary, so it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA).
2021-06-23 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by TG Therapeutics, Inc. It reports on the results of the 2021 Annual Meeting of stockholders, including voting results on director elections and an amendment to the certificate of incorporation increasing authorized shares. The document includes detailed voting results and a certificate of amendment as an exhibit. The primary content is the submission of matters to a vote of security holders, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document is not an annual report, earnings release, or management discussion, but specifically reports official shareholder vote results from the annual meeting. The length and detail confirm it is not a brief announcement or proxy solicitation but the actual voting results report.
2021-06-21 English
10-Q
Interim / Quarterly Report Q1 2021
2021-05-10 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and states that a press release announcing results for the quarter ended March 31, 2021, is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references a press release. The length is only 3013 characters, which is short and consistent with an announcement rather than a full report. According to the rules, such a document is best classified as an Earnings Release (ER) since it announces quarterly financial results highlights via a press release, not the full quarterly report (which would be an Interim/Quarterly Report IR).
2021-05-10 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.